Cephapirin Sodium

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 317458

CAS#: 24356-60-3

Description: Cephapirin Sodium is the sodium salt form of cephapirin, a semi-synthetic, broad-spectrum, first-generation cephalosporin antibiotic. It is beta-lactam with bactericidal activity. Cephalosporin antibiotic is effective against gram-negative and gram-positive organisms. Cephapirin sodium inhibits bacterial cell wall synthesis by inhibiting the final transpeptidation step of peptidoglycan synthesis and subsequent cross-linking of peptidoglycan units.

Chemical Structure

Cephapirin Sodium
CAS# 24356-60-3

Theoretical Analysis

MedKoo Cat#: 317458
Name: Cephapirin Sodium
CAS#: 24356-60-3
Chemical Formula: C17H16N3NaO6S2
Exact Mass:
Molecular Weight: 445.44
Elemental Analysis: C, 45.84; H, 3.62; N, 9.43; Na, 5.16; O, 21.55; S, 14.40

Price and Availability

Size Price Availability Quantity
10.0mg USD 250.0 2 Weeks
25.0mg USD 450.0 2 Weeks
100.0mg USD 750.0 2 Weeks
Bulk inquiry

Synonym: Cephapirin Sodium; Cefapirin sodium; Cephap; BL P 1322; BL-P 1322; BLP 1322. NSC 179171

IUPAC/Chemical Name: sodium;(6R,7R)-3-(acetyloxymethyl)-8-oxo-7-[(2-pyridin-4-ylsulfanylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate


InChi Code: InChI=1S/C17H17N3O6S2.Na/c1-9(21)26-6-10-7-28-16-13(15(23)20(16)14(10)17(24)25)19-12(22)8-27-11-2-4-18-5-3-11;/h2-5,13,16H,6-8H2,1H3,(H,19,22)(H,24,25);/q;+1/p-1

SMILES Code: CC(=O)OCC1=C(N2C(C(C2=O)NC(=O)CSC3=CC=NC=C3)SC1)C(=O)[O-].[Na+]

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 445.44 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Gorden PJ, van der List M, Lehman FD, Lantz RK, Constable PD. Elimination
kinetics of cephapirin sodium in milk after an 8-day extended therapy program of
daily intramammary infusion in healthy lactating Holstein-Friesian cows. J Dairy
Sci. 2013 Jul;96(7):4455-64. doi: 10.3168/jds.2012-6487. Epub 2013 May 16. PubMed
PMID: 23684021.

2: Roy JP, DesCôteaux L, DuTremblay D, Beaudry F, Elsener J. Efficacy of a 5-day
extended therapy program during lactation with cephapirin sodium in dairy cows
chronically infected with Staphylococcus aureus. Can Vet J. 2009
Dec;50(12):1257-62. PubMed PMID: 20190974; PubMed Central PMCID: PMC2777288.

3: Stockler RM, Morin DE, Lantz RK, Hurley WL, Constable PD. Effect of milk
fraction on concentrations of cephapirin and desacetylcephapirin in bovine milk
after intramammary infusion of cephapirin sodium. J Vet Pharmacol Ther. 2009
Aug;32(4):345-52. doi: 10.1111/j.1365-2885.2008.01048.x. PubMed PMID: 19614839.

4: Apparao MD, Ruegg PL, Lago A, Godden S, Bey R, Leslie K. Relationship between
in vitro susceptibility test results and treatment outcomes for gram-positive
mastitis pathogens following treatment with cephapirin sodium. J Dairy Sci. 2009
Jun;92(6):2589-97. doi: 10.3168/jds.2008-1693. PubMed PMID: 19447991.

5: Rosenberg JB, Love B, Patterson DL. Bacterial cure and somatic cell count
response of dairy cows with a positive California Mastitis Test at calving to
therapy with cephapirin sodium. Vet Ther. 2002 Winter;3(4):381-6. PubMed PMID:

6: Morelli B. "Zero-crossing" derivative spectrophotometric determination of
mixtures of cephapirin sodium and cefuroxime sodium in pure form and in
injections. Analyst. 1988 Jul;113(7):1077-82. PubMed PMID: 3223581.

7: Hilleman DE, McEvoy GK, Bailey RT Jr, Reich J. Stability of cephapirin sodium
admixtures after freezing and conventional or microwave thaw techniques. Hosp
Pharm. 1984 Mar;19(3):202, 207, 211-3. PubMed PMID: 10265849.

8: Imoto T. [Pharmacokinetics of cephapirin sodium during intravenous infusion].
Jpn J Antibiot. 1983 Aug;36(8):2120-8. Japanese. PubMed PMID: 6655830.

9: Murray WR, Jameson E. The clinical use of cephapirin sodium in total hip
arthroplasty and measurement of plasma and bone levels. Orthopedics. 1980 Feb
1;3(2):131-4. doi: 10.3928/0147-7447-19800201-07. PubMed PMID: 24822936.

10: Fry W, Ximenes J, Siskin SB. Concentrations of cephapirin sodium in plasma
and gynecologic tissue after a single preoperative dose. Int J Clin Pharmacol
Ther Toxicol. 1980;18(2):92-6. PubMed PMID: 7372381.

11: Prasad VK, Johns WH, Wingate MW, Mihotic MM, Southard BJ, Kaplan MA, Granatek
AP. Pharmaceutics of cephapirin sodium (Cefadyl) a new semisynthetic
cephalosporin - part III. Curr Ther Res Clin Exp. 1974 Nov;16(11):1214-37. PubMed
PMID: 4214656.

12: Prasad VK, Granatek AP, Mihotic MM. Physical compatibility and chemical
stability of cephapirin sodium in combination with antibiotics and large-volume
parenteral solutions. I. Curr Ther Res Clin Exp. 1974 May;16(0):505-39. PubMed
PMID: 4365711.

13: Prasad VK, Granatek AP, Mihotic MM. Physical compatibility and chemical
stability of cephapirin sodium in combination with non-antibiotic drugs in
large-volume parenteral solutions. II. Curr Ther Res Clin Exp. 1974
May;16(0):540-72. PubMed PMID: 4209520.

14: Kaplan MA, Granatek AP. Stability of frozen solutions of cephapirin sodium.
Curr Ther Res Clin Exp. 1974 May;16(0):573-9. PubMed PMID: 4209055.

15: Khan AJ, Pryles CV. Clinical and pharmacological evaluation of cephapirin
sodium (BL-P-1322) in infants and children (cephapirin in pediatric patients).
Curr Ther Res Clin Exp. 1973 Apr;15(4):198-204. PubMed PMID: 4633280.

16: McCloskey RV, Terry EE, McCracken AW, Sweeney MJ, Forland MF. Effect of
hemodialysis and renal failure on serum and urine concentrations of cephapirin
sodium. Antimicrob Agents Chemother. 1972 Feb;1(2):90-3. PubMed PMID: 4680808;
PubMed Central PMCID: PMC444174.

17: Gordon RC, Barrett FF, Clark DJ, Yow MD. Laboratory and pharmacologic studies
of BL-P-1322 (cephapirin sodium) in children. Curr Ther Res Clin Exp. 1971
Jun;13(6):398-406. PubMed PMID: 4996227.